News

News 15.04.2026 Collaboration supports global LRRK2 Investigative Therapeutics Exchange (LITE) to accelerate development of reliable biomarkers for Parkinson’s disease April 14, 2026 – ZURICH, Switzerland. Biognosys Group, a leading provider of proteomics, metabolomics, and lipidomics solutions, today announced a major collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance the...

News 14.04.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that...

News 14.04.2026 Schlieren, ZH/Bern – Biognosys will present four scientific talks at this year’s Swiss Proteomics Meeting. The event for proteomics and life sciences will take place on April 23 and 24 at the Holiday Inn Bern – Westside. According to a press release, the Schlieren-based biotech company will participate in the meeting...

News 14.04.2026 Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Financial Highlights Total product sales rose by 51% to USD 43.4 million (Q1 2025: USD 28.8 million) Direct MagnetOs™ product sales increased by 51% to...

News 10.04.2026 New research from Zurich shows that the gut microbiome may have an impact on cancer immunotherapy, giving patients who did not initially respond to treatment a second chance. In recent years, cancer immunotherapy has been one of the greatest advances in the field of oncology. Unlike chemotherapy and radiotherapy, this treatment...